Working… Menu

Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00120367
Recruitment Status : Completed
First Posted : July 18, 2005
Last Update Posted : December 22, 2011
Hoffmann-La Roche
Gilead Sciences
Information provided by (Responsible Party):
French National Agency for Research on AIDS and Viral Hepatitis

Brief Summary:

Progressive multifocal leucoencephalopathy (PML) is a rare infectious disease of the brain, provoked by the JC virus. It usually occurs in subjects with impaired immune system as during HIV infection. To date, there is no specific antiviral treatment susceptible to cure PML. But it was shown in the setting of HIV-related PML, that combination antiretroviral therapy allows a restoration of the immune system and then might stop the progression of PML.

The objective of this study is to appreciate the supplementary efficiency brought by an association of more powerful antiretroviral molecules including enfuvirtide on the evolution of PML. This research program will involve 30 patients in several centres in France. All the patients who will participate will receive enfuvirtide during 6 months in association with a combination of two or more potent antiretroviral drugs. The total duration of follow-up for a patient will be of 1 year.

Condition or disease Intervention/treatment Phase
Leukoencephalopathy, Progressive Multifocal HIV Infections Drug: Enfuvirtide Drug: Tenofovir-Emtricitabine Phase 2

Detailed Description:

The aim of this open-label multicentre study is to estimate the effect of an early therapy intensification based on potent antiretroviral combination including enfuvirtide(FUZEON®) on survival in patients with HIV-1-related progressive multifocal leucoencephalopathy (PML).

To demonstrate that the observed rate is significantly superior to 45%, the inclusion of 24 patients is necessary. At last, 30 patients will be recruited towards the risk estimated at 25% of invalid inclusion.

Patients will be included on the following criteria : HIV-1 documented by Western Blot, clinical and radiological (MRI) evidence of active LEMP with clinical evolution (or deterioration) for less than 90 days, documentation of PML diagnosis for less than 30 days at the inclusion, informed consent (patient or confidence surrogate if decision making incapacity). Exclusion criteria will be the following: age less than 18-year-old ; concomitant opportunistic infection of the central nervous system; pregnancy - feeding; co-infection by the HIV2; history of immunotherapy (interleukin 2, alpha-interferon) or of treatment by FUZEON®; history of treatment by cidofovir; contra-indication to receive FUZEON ®.

An independent committee will meet regularly to estimate the validity of PML diagnosis in included patients.

The duration of the treatment by FUZEON® is 6 months in association with a combination of two or more antiretroviral molecules which will be pursued during the next 6 months. These molecules will be chosen according to the past treatment of the patients. A combination including efavirenz, lopinavir/ritonavir, and tenofovir/emtricitabine (under the shape of TRUVADA®) will be proposed to the naïve patients. For the pretreated patient(approximately a quarter of the inclusions), antiretroviral therapy will be chosen in every case on the basis of the therapeutic history and of the viral genotypes of resistance. Such association will contain at least two antiretroviral molecules, issued from two different families among the three following ones (nucleoside inhibitors of the reverse transcriptase, non-nucleoside inhibitors of the reverse transcriptase, protease inhibitors).

The projected duration of the period of inclusion will be 18 months. A total duration of 2.5 years is projected.

Evaluation criteria of the ANRS 125 trial are the following. Clinical: rate of survival and functional score (Modified Rankin Outcome Scale) to M12. Virological: evolution of the JC viral load in the CSF ; and percentage of patients with JC virus clearance of the CSF to M3 and M6. Immunological: evolution of T CD4 and T CD8 subpopulations. Evolution of the anti-JC virus specific T cell (CD4 and CD8) responses. Pharmacological: dosage of the concentration of enfuvirtide in the CSF compared with the plasma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Early Intensification of Combination Antiretroviral Therapy Including FUZEON® in the Treatment of Progressive Multifocal Leucoencephalopathy During HIV-1 Infection ANRS 125 Trial
Study Start Date : April 2005
Actual Primary Completion Date : December 2007
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
Drug Information available for: Enfuvirtide

Primary Outcome Measures :
  1. Estimation by the method of Kaplan-Meier of the rate of survival at M12

Secondary Outcome Measures :
  1. Rate of survival and functional score (Modified Rankin Outcome Scale) at M12
  2. Evolution of the JC viral load in the CSF and percentage of patients with JC virus clearance of the CSF to M3 and M6
  3. Evolution of the CD4 and CD8 T cells sub-populations and of the antivirus JC specific T cell responses at M12
  4. Dosage of the concentration of enfuvirtide in the CSF

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age and older
  • Have confirmed laboratory diagnosis of HIV infection
  • Presenting with a clinical history of active PML evolving (or continuing to deteriorate) for less than 90 days
  • Diagnosis of PML documented for less than 30 days at the inclusion by cerebral imaging (MRI) AND the absence of another demonstrated etiology AND the detection of JCV DNA in the CSF by qualitative PCR.
  • Signed written inform consent

Exclusion Criteria:

  • Concomitant opportunistic infection of the central nervous system
  • Pregnancy, breast-feeding
  • Co-infection by the HIV2
  • History of immunotherapy including interleukin-2 and alpha-interferon
  • History of treatment by FUZEON® or by cidofovir
  • Contra-indication to receive FUZEON

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00120367

Layout table for location information
Service de Medecine interne et Maladies Infectieuses, Hopital Bicetre
Le Kremlin Bicetre, France, 94270
Sponsors and Collaborators
French National Agency for Research on AIDS and Viral Hepatitis
Hoffmann-La Roche
Gilead Sciences
Layout table for investigator information
Principal Investigator: Jacques Gasnault, MD Hopital Bicetre Kremlin Bicetre France
Study Chair: Dominique Costagliola Inserm U720
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: French National Agency for Research on AIDS and Viral Hepatitis Identifier: NCT00120367    
Other Study ID Numbers: 2005-000424-16
ANRS 125
First Posted: July 18, 2005    Key Record Dates
Last Update Posted: December 22, 2011
Last Verified: December 2011
Keywords provided by French National Agency for Research on AIDS and Viral Hepatitis:
Leukoencephalopathy, Progressive Multifocal
HIV infections
HIV Fusion Inhibitors
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Leukoencephalopathy, Progressive Multifocal
Communicable Diseases
Blood-Borne Infections
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Encephalitis, Viral
Central Nervous System Viral Diseases
Central Nervous System Infections
Infectious Encephalitis
Polyomavirus Infections
DNA Virus Infections
Demyelinating Diseases
Antiviral Agents